Becton Dickinson and Co vs Nerdwallet Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Nerdwallet Inc trades at $9.57 (market cap $616.53M). The key difference: Becton Dickinson and Co is far larger — about 67.3× Nerdwallet Inc's market cap, and Becton Dickinson and Co pays a 2.79% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals.
| BDX | NRDS | |
|---|---|---|
Market Cap | $41.51B | $616.53M |
Sector | Health | Financials |
52-Week High | $185.39 | $15.93 |
52-Week Low | $135.49 | $7.58 |
Enterprise Value | $57.97B | $530.83M |
Dividend Yield | 2.79% | — |
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
NerdWallet (NRDS) trades at $9.49, up 0.21% today, with a bullish technical signal from moving averages and strong fundamental momentum. The company reported revenue of $836.6M in 2025, with net income of $48.7M and a net margin of 5.82%, showing a clear turnaround from losses in prior years. Recent earnings beats, including Q1 2026 EPS of $0.29 versus $0.25 expected, underscore operational strength. Analyst consensus is bullish with a $12.75 price target, implying 34% upside.
The outlook is positive given valuation multiples like a P/E of 10.2 and EV/EBITDA of 3.87, which appear attractive relative to growth. Key risks include reliance on search-driven traffic and macroeconomic sensitivity. Continued execution on revenue diversification and cost control supports further upside, but investors should monitor competitive pressures and consumer spending trends.
Trailing returns across standard periods
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →